In the second of two articles on rare causes of dementia, the authors describe toxic, iatrogenic, nutritional, traumatic, metabolic, neoplastic and autoimmune causes of dementia. Disorders are graded according to their prevalence, to give an idea of the likelihood of their presentation. Guidance is given on the investigation of uncommon cognitive impairment and dementia, especially in early-onset illness.
ARTICLE
The number of people affected by dementia contin ues to rise year on year. A large variety of factors can lead to this progressive, debilitating condition and understanding these is vital in addressing this growing problem. The most common causes of dementia, such as Alzheimer's disease and Lewy body disease, account for 95% of cases and have been widely researched. However, it is important not to forget the rarer causes, which account for the remaining 5%. They affect a small but equally important patient group and very little is written about them in the literature.
Rare and unusual causes of dementia are proportionally more common in people under 65 years of age. † They often present first to neurolo gists, especially if the patients are younger and have physical symptoms. However, mental health services are sometimes involved before neurology, because of early presentation with mood or psychotic symptoms or behavioural disturbances. Psychiatric teams may be involved at various stages of assessment and management, and in some situations they are the first point of contact for the patient, for example through youngonset dementia services or liaison psychiatry.
In a previous issue of Advances, we described rare dementias with degenerative, vascular, prion and infectious causes (Gupta 2009 ). Here we will describe other rare and unusual causes of dementia, which we might categorise as being of 'exogenous' (toxicity, vitamin deficiency, brain damage) or 'endogenous' (endocrine and other organ failure, compromised metabolism, neoplasia, autoimmunity) origin. We will start with exogenous factors (Box 1).
Toxicity

Heavy metals
Lead Dementia caused by heavy metals poisoning is most commonly due to chronic exposure to lead. Causes of chronic lead poisoning include exposure in industrial workplaces, drinking water supplied through lead pipes and accidental ingestion, for example by ingesting paint (Wills 2006) .
Inorganic forms of lead (for example, in paint, and ground and surface water) typically affect the central and peripheral nervous systems and the haematopoietic, renal, gastrointestinal and repro ductive systems. The rarer organic forms (such as tetraethyl lead used in petroleum products) affect the central nervous system (CNS) . Lead poisoning presents with a combination of gastrointestinal, haematological (lead interferes with haemoglobin synthesis) and neurological symptoms, including fatigue, depression, confusion, peripheral neuro pathy, cognitive impairment, encephalopathy and seizures. A gray or bluish black lead line may be visible at the gingival border.
Diagnosis is based on history, clinical features and venous blood levels. A blood lead level >10 mg/dL is considered toxic. Normocytic or microcytic anaemia and nonspecific red cell basophilic stippling on peripheral blood smears are common. Treatment with chelating agents such as eden tate calcium disodium, dimercapto succinic acid (DMSA) or dimercaprol reduces the body stores of lead (Chisolm 1990) .
Mercury, arsenic and manganese
Dementia caused by chronic mercury poisoning presents in some industrial workers (mercury occurs in certain batteries, paints and industrial wastes). Symptoms include peripheral neuro pathy, ataxia and fine tremor, progressing to cerebellar (intention) tremor, choreoathetosis and dementia. Chronic arsenic ingestion causes confusion, memory loss, peripheral neuropathy, 'raindrop pigmentation' of the skin and transverse white lines on the fingernails (Mae's lines). Treatment for both mercury and arsenic poisoning is chelation therapy (Wills 2006) .
Manganese toxicity has been suggested as a cause of dementia (Dobson 2004) . In conjunction with genetic predisposition, manganese exposure might play an important role in causing Parkinsonian disturbances, possibly enhancing physiological ageing of the brain (Zatta 2003) .
Aluminium
Aluminium toxicity (dialysis dementia syndrome) can occur secondary to dialysis using water containing aluminium. The syndrome has been mostly eliminated by the use of deionised water.
Untreated patients can develop progressive encephalopathy, confusion, memory loss, agitation, lethargy, myoclonic jerks and stupor. Electroencephalography (EEG) shows non specific generalised changes. Postmortem studies show high brain aluminium content without neurofibrillary tangles or amyloid plaques.
A causal link between aluminium and Alz heimer's disease had been suggested, but a direct relationship has not been found (Campbell 2002) .
Organophosphates and pesticides
It has been suggested that environmental exposure to organophosphates and other pesticides is associated with various neurodegenerative processes (Kamel 2004) . There is mounting evidence that chronic moderate exposure to pesticides is neurotoxic and increases the risk of Parkinson's disease, amyotrophic lateral sclerosis, mild cognitive impairment (similar to that described in the Gulf War syndrome) and dementia (Hayden 2010) . ‡
Medications Lithium
The relationship between lithium and dementia is unclear. Subjective complaints by those taking lithium of mental slowness are not uncommon but a longerterm effect remains controversial. One review found a subtle impairment of psychomotor speed and verbal memory but not of visuospatial ability, attention or concentration (Pachet 2003) . Other studies have suggested that lithium in bipolar affective disorder has a protective effect against dementia, owing to its inhibition of Alzheimer's disease pathogenesis (Nunes 2007) . Acute lithium toxicity can present with cognitive impairment. Investigations in patients on lithium showing cognitive impairment should include measurement of lithium level and routine blood, renal (to exclude chronic renal failure) and thyroid function tests. Adjunctive thyroid hormone may improve cognitive functioning as thyroid levels are restored.
Interferon
Interferon is used in immunotherapy for treatment of cancer and viral infections. Neurological effects of interferon alpha are more common in older age groups, in those treated with higher doses, in those with longer treatment duration, and when used in combination with other medications that affect cognition (Merimsky 1992) . Patients may exhibit mild to moderate symptoms of frontal subcortical brain dysfunction, including cognitive slowing, apathy and executive dysfunction. Neurotoxicity may be mediated through neuroendocrine, neuro transmitter or cytokine pathways. Neuroimaging studies show decreased prefrontal metabolism with interferon alpha therapy. Opiate antagonists could be helpful in treating the cognitive impairment (Valentine 1995) .
Steroids
Iatrogenic glucocorticosteroid dementia syndrome is often unrecognised but occurs in about 1 in 250 people treated with steroids (Varney 1984) and is more common in the elderly. The syndrome may reflect steroid neurotoxicity. Glucocorticosteroids may affect hippocampal volume (Wolkowitz 2004) . Clinically, there is transient impairment of attention, concentration and memory. Cushingoid features such as facial puffiness and weight gain may be present. Diagnosis requires a history of glucocorticosteroid use and cortisol assay. Symp toms are usually reversible with discontinuation but in rare cases problems may initially worsen or persist. ‡ 
Articles of related interest in
Alcohol and recreational drugs
Heavy use of alcohol and tobacco, both legal, are known to have longterm effects on cognition and contribute to development of dementia (Hulse 2005) . Chronic heavy alcohol consumption can cause acute Wernicke encephalopathy, followed by Korsakoff syndrome or alcoholrelated dementia (Gupta 2008) . However, light to moderate alcohol use may have a protective effect on cognition.
A few studies (e.g. Rosselli 1996; Hulse 2005 ) have looked at the cognitive sideeffects of drugs such as cannabis, ecstasy and cocaine. Some have linked them with various types of cognitive impairment (both shortterm and chronic), but evidence to suggest direct causality is still not conclusive. Polysubstance use and concomitant use of alcohol might compound the problem.
Vitamin deficiency
Niacin deficiency (pellagra)
Pellagra is mostly found in parts of the world with niacin or tryptophanpoor diets. In the West, it is most common in alcoholism, Hartnup disease (a congenital defect in tryptophan absorption) and carcinoid syndrome (increased conversion of hydroxytryptophan to serotonin).
The classic presentation includes dementia, haemorrhage, dermatitis (Casal collar -dermatitis around the neck) and diarrhoea. Myoclonus, ataxia and seizures may also occur (Wills 2006) .
The diagnosis is based on detection of low levels of the urinary metabolites 2methylnicotinamide and 2pyridone. Treatment is with oral niacin.
Folate deficiency
Congenital errors of folate transport and metabo lism produce developmental delay, cognitive deterioration, motor and gait abnormality, seizures, and vascular and demyelinating changes. Deficiency is caused by inadequate intake, increased requirements, malabsorption and impaired metabolism. Folate and vitamin B 12 deficiency both lead to impaired methylation and accumulation of homocysteine. In Alzheimer's disease, high plasma homocysteine levels are associated with more rapid atrophy of the medial temporal lobes (Clarke 1998) .
Patients may present with peripheral neuro pathy, depression, apathy, withdrawal and mild to moderate dementia. Investigations show megaloblastic anaemia, low serum and cerebrospinal fluid (CSF) folate and raised homocysteine. Neuropsychological symptoms respond much more slowly to folate replacement than do haematological symptoms.
Vitamin B 12 deficiency
Vitamin B 12 deficiency can be caused by inade quate intake (e.g. in the vegan diet), malabsorption due to defective release of gastric intrinsic factor (gastric achlorhydria, partial gastrectomy), inad equate production of intrinsic factor (pernicious anaemia, total gastrectomy), disorders of the terminal ileum (tropical and nontropical spruce, intestinal resection), competition for cobalamin (fish tapeworm, 'blind loop' syndrome), drugs (colchicines, neomycin) and Crohn's disease. The mechanism of neurological damage may be related to Sadenosylmethionine deficiency. Damage to cerebral myelinated fibres may also cause dementia. Neurological complications include sensory neuropathy (more common in the upper limbs), myelopathy, optic nerve dysfunction, positive Romberg's test and altered cognition. Spinal cord involvement may occur. Blood tests may show low vitamin B 12 level, megaloblastic anaemia, macro cytosis and target cells, but neuro logical dysfunction can occur with normal haematological parameters (Wills 2006) .
Early treatment with parenteral vitamin B 12 stops progression but rarely reverses advanced damage to the nervous system. In cases of both folate and vitamin B 12 deficiencies, the latter should be replaced first, to prevent precipitation of subacute combined degeneration of the umbilical cord.
Head trauma and diffuse brain damage
Dementia pugilistica ('punch drunk' syndrome)
Dementia pugilistica, caused by recurrent head trauma, is mostly found in boxing, affecting about 20% of professional boxers. Symptoms are progressive and begin late (even many years after retirement). Severity depends on length of career and number of bouts fought. There is profound loss of pigmented neurons in the substantia nigra, without Lewy bodies (Fleminger 2003) . The ex tent of dementia is variable, with slow progression. The syndrome is characterised by extrapyramidal symptoms, ataxia, intention tremor, and cognitive and personality change, which help to differentiate it from Alzheimer's disease. There is progressive social decline. Treatment with drugs for Alzhei mer's disease or Parkinsonism may be useful.
Anoxic brain injury/delayed post-anoxic encephalopathy
Severe cerebral hypoxia is usually due to carbon monoxide poisoning, cardiac and respiratory arrest and attempted hanging. Most patients with carbon monoxide poisoning recover well, but 10-30% develop delayed neuropsychiatric sequelae such as cognitive and personality changes, incontinence, dementia and psychosis (Ernst 1998) . About 10% develop Parkinsonism (Choi 2002) . Memory im pairment is probably due to hippocampal changes (ZolaMorgan 1986). Computed tomography and diffusion weighted magnetic resonance imaging (MRI) show low density in the cerebral white matter and lesions in the globus pallidus. Levodopa and anticholinergic drugs are unlikely to reverse Parkinsonian features.
Head injury
Acute head injury with loss of consciousness can cause anterograde and retrograde amnesia. The relationship between remote head injury and dementia is unclear. One large study found that mild head trauma did not increase the risk of dementia or Alzheimer's disease in older people (Mehta 1999) . However, other studies have suggested that previous head trauma is associated with risk of developing Alzheimer's disease (Fleminger 2003) .
Normal-pressure hydrocephalus
Normalpressure hydrocephalus is seen in 6-10% of all dementia patients (Alzheimer Europe 2009). The pathophysiology is unclear but there is a possible cerebrovascular role. The classic triad includes: (a) early gait disturbance characterised by proximal weakness and short, shuffling, broadbased gait; (b) urinary incontinence; and (c) dementia -predominantly subcortical with frontal lobe involvement in later stages, characterised by prominent memory loss and bradyphrenia. Cortical features such as aphasia, agnosia and apraxia are generally absent. Computed tomography (CT) or MRI show ventricular enlargement, a prominent flow void in the aqueduct and third ventricle (the 'jet sign') and rounding of the frontal horns. In 50% of cases, EEG shows beta oscillations with bursts of monorhythmic bilateral theta and delta waves. Lumbar puncture to measure cerebrospinal fluid pressure is considered the diagnostic gold standard, but it has a high incidence of false negatives. Insertion of a ventriculoperitoneal shunt improves symptoms in 30-40% of patients, but with a relatively high incidence of complications such as strokes or seizures.
Chronic subdural haematoma
Chronic subdural haematoma is a common treatable cause of dementia, with an annual population prevalence of between 1.2 and 7.3 per 100 000 (Fogelholm 1975 ) and a male to female ratio of 2:1. Older individuals with cerebral atrophy are vulnerable and 25-50% of patients have no identifiable history of head trauma (spontaneous or idiopathic subdural haematoma). Risk factors include chronic alcoholism, epilepsy, arachnoid cyst, coagulopathy, anticoagulation therapy and cardiovascular disease. Clinical presentation is often insidious, with altered consciousness, focal neurological deficits (subtle changes to hemiparesis), headache, gait and balance abnormalities and seizures. Brain scans help diagnosis. Treatment is by surgical evacuation. Patients with chronic alcoholism and pneumocephalus have poor outcomes.
We will now examine various 'endogenous' causes of rare dementias (Box 2).
Endocrine and other organ failure
Hypothyroidism
Hypothyroidism is up to six times more com mon in women than in men (Vanderpump 1995 
Hyperparathyroidism
Primary hyperparathyroidism is caused by solitary adenomas (80%) or as part of multiple endocrine neoplasia. The incidence of primary hyperparathyroidism is believed to be between 0.01 and 0.1% (Zahrani 1997 ), but in people over 60 years of age it may be as high as 0.2%, with a prevalence of 1.0% or greater in this elderly population (Watson 2002) . The incidence peaks between the third and fifth decades. Patients present with recurrent renal calculi, peptic ulcers and extensive bone resorption. Over half of those affected present with neuropsychiatric manifestations such as depression, apathy and cognitive impairment (Geffken 1998 
Diabetes mellitus
In patients with earlyonset diabetes and those with poor glycaemic control, the presence of micro and macrovascular disease may cause early cognitive deficits. Hypertension, dyslipidaemia and obesity are associated with diabetes and increase the risk of dementia. The most common impairments are in verbal memory, attention, semantic and language functions and processing speed, with relatively preserved visuospatial functioning (Awad 2004) . Cognitive deficits are also observed in older, untreated patients but improve with glycaemic control.
Renal encephalopathy
Dementia due to renal failure usually has potentially reversible causes. These include uraemic encephalopathy with parathyroid hormone dys function, dialysis dementia syndrome and dialysisassociated encephalopathy. Uraemic encephalopathy develops when the glomerular filtration rate declines below 10% (Alzheimer Europe 2009). Neurological and cognitive symptoms in renal encephalopathy can fluctuate. Early symptoms of anorexia, nausea and restlessness progress to vomiting, confusion with cognitive impairment, seizures, stupor and coma. Physical signs include nystagmus, papilloedema, hyperreflexia and asterixis. Investigations include renal function tests, creatinine clearance rates (below 15 mL/ min), calcium, phosphate, magnesium and parathyroid hormone levels, and toxicology. Blood pressure and electrocardiography (ECG) need to be monitored. Electroencephalography (EEG) shows generalised slowing.
The treatment of renal encephalopathy requires addressing any hypertension, diabetes, lipid prob lems, acidosis and hyperkalaemia, in a specialist setting. Dialysis may reverse uraemic encepha lopathy. Parathyroidectomy, medical parathyroid hormone suppression, erythropoietin treatment or renal transplant may also be needed.
Hepatic encephalopathy
Chronic neuropsychiatric conditions are seen in cirrhosis, portal hypertension, fulminant hepatic failure and following portosystemic shunt procedures (e.g. transjugular intrahepatic portosystemic shunts, TIPS). This potentially reversible condition is caused by accumulation of toxic metabolites such as ammonia, which bypass the liver and alter brain neurotransmitter balance. Acute onset is often precipitated by high dietary protein intake, gastrointestinal haemorrhage, constipation, infection, electrolyte imbalance, shunting procedures and drugs such as CNS depressants). Neurological signs include poor attention, restlessness, uncoordination and lethargy, which progress to delirium, stupor, seizures and coma. There may be a chronic progressive course with cognitive blunting and confusional states (Alzheimer Europe 2009). Physical signs include asterixis, foetor hepaticus, constructional apraxia and decreased mental ability. Diagnosis is clinical, supported by routine biochemistry. An EEG will show decreased alpha and increased delta waves.
Management consists of restricting protein intake, correcting electrolyte imbalances and treating the underlying cause. Lactulose and flumazenil can induce transient improvement. A liver transplant may be needed.
metabolic and other conditions
Wilson's disease
Wilson's disease has a population prevalence of 3.3/100 000. Cognitive impairment is rare and ranges in severity from mild to moderate (Sternlieb 1990) . It is an autosomal recessive disorder casued by mutations of the coppertransporting adenosine triphosphatase (ATPase) gene on chromosome 13q. There is abnormal copper deposition in the liver (causing cirrhotic changes), brain (lenticular nuclei), kidneys and corneas (Kayser-Fleischer rings), due to impaired biliary copper excretion. Onset usually occurs between 5 and 30 years of age and rarely after middle age. Affect, behaviour and personality abnormalities are common clinical features. Neurological features include orofacial dystonia, dysarthria, dysphagia, dystonic postures, tremor and Parkinsonism.
Diagnosis is based on neurological and ophthalmological examination, ceruloplasmin levels and liver function abnormality and is confirmed by liver biopsy. Brain imaging may indicate enlarged ventricles with cortical and brain stem atrophy, in addition to T 2 hyperintensities in the basal ganglia.
Treatment is with the copperchelating agent penicillamine.
Metachromatic leukodystrophy
Metachromatic leukodystrophy is a demyelinating storage disease caused by deficiency of the lysosomal enzyme arylsulfatase A (ARSA). It is an autosomal recessive inherited metabolic disease with late juvenile and adult onset. Clinical presentation includes personality and behavioural changes, gradual loss of motor skills, optic atrophy, seizures, cognitive deficits and dementia (Estrov 2000) . Nonspecific white matter lesions are evident on MRI. Cerebrospinal fluid proteins may be increased, and ARSA enzyme activity may be decreased in leukocytes or in cultured skin fibroblasts. DNA mutation analysis can be done. Treatment is symptomatic and supportive.
Adrenoleukodystrophy and adreno myeloneuropathy
This disorder affects 1/20 000 males either as cerebral adrenoleukodystrophy (ADL) in children or as adrenomyeloneuropathy (AMN) in adults (Mosser 1993) . The neonatal form is autosomal recessive, whereas the adult form is Xlinked. Women are carriers and have milder presentations if affected. The defect lies in the gene ABCD1. There is an accumulation of very longchain saturated fatty acids such as hexacosanoate in lipidcontaining tissue in the brain, with characteristic lamellar inclusions in the Schwann cells of the CNS and the adrenal cortex. There are characteristic lamellar inclusions in the Schwann cells of the CNS and adrenal cortex, leading to noninflammatory axonopathy involving the spinal cord.
Adrenomyelo neuropathy is the milder form, with onset at 15-30 years of age and a progressive course. It affects the brain, spinal cord, adrenal glands and testes. Clinical features include spastic paraparesis, ataxia and sensory loss of lower limbs, language difficulties and adrenal insufficiency. Rarely, focal signs and memory problems may mimic Alzheimer's disease. Adrenal insufficiency progresses to Addison's disease (also known as chronic or primary adrenal insufficiency, hypocortisolism or hypoadrenalism). Biochemical assay of body fluids and biopsy of skin and conjunctival nerve terminals are useful in diagnosis. Treatment is symptomatic with adrenal hormone replacement and haematopoietic stem cell transplantation. Psychological support and physiotherapy are helpful.
Neurodegeneration with brain iron accumulation type-1 (NBIA1) or Hallervorden-Spatz syndrome
There are about 100 published cases of this condition (Alzheimer Europe 2009). Familial occurrences are more common, with autosomal recessive inheritance. There is neuroaxonal dystrophy and iron accumulation in the basal ganglia. 
Neuroacanthocytosis
This is a group of phenotypically and genetically hetero geneous disorders. Neuroacanthocytosis occurs through autosomal dominant, autosomal recessive or Xlinked inheritance or, in sporadic cases, with recessive mutations in the chorein gene on chromosome 9 or Xlinked mutation (Jarman 2002) . There may be choreiform or Parkinsonian features, neuropathy, muscle wasting, dementia and acanthocytosis. Depression, personality changes and paranoia may occur. Symptoms may progress slowly. At least half of patients develop subcortical dementia with executive and visuospatial difficulties, and anomia in later stages. Onset is usually in early middle age. Blood tests show acanthocytes (abnormal blood cells with spiny protuberances) in fresh samples with normal lipid metabolism (this differentiates the disease from acanthocytosis in abetalipoproteinaemia -Bassen-Kornzweig syndrome). Serum creatinine kinase may be abnormal. Computed tomography often shows caudate or generalised atrophy; T 2 weighted MRI may show abnormal signals from basal ganglia. No specific treatment exists for the primary disease. Antipsychotics or tetrabenazine may be useful for chorea.
Cerebral lipidoses -adult variant
Cerebral lipidoses are a group of lysosomal storage diseases, with Xlinked or autosomal recessive transmission. Rare adult forms may cause cognitive impairment. Tay-Sachs disease (also known as hexosaminidase A deficiency) and Sandhoff disease (Jatzkewitz-Pilz syndrome, hexosaminidase A and B deficiency) are caused by mutation in the HEXA or HEXB genes on chromosome 15. They present with progressive lower limb weakness, cerebellar atrophy, denervation motor neuron disease and dementia.
Chronic type I (nonneuropathic) Gaucher disease, which rarely affects adults, can lead to dementia, spastic paraplegia, seizures, behavioural problems and psychosis. Types C and D Niemann-Pick disease (sphingomyelin lipidosis, sphingomyelinase deficiency) presents with neurological and cognitive impairment due to accumulation of sphingomyelin. No established treatment is available for improving cognitive impairment, although enzyme replacement (in Gaucher disease) and a lowcholesterol diet (in Niemann-Pick disease) have been tried.
neoplasms and paraneoplastic disorder
Cerebral tumours are a rare cause of dementia. The most prevalent are frontal meningiomas, multiple metastases and temporal gliomas. Clinical features are related to the site of the tumour, its extent and progress. Even less common causes include neoplastic angioendotheliosis, which cause subacute dementia, and lymphomatosis cerebri (primary lymphoma of the CNS without evidence of a mass lesion), which causes rapidly progressing dementia. Tumours of the anterior corpus callosum present with apathy, mental dullness and poor shortterm memory.
Paraneoplastic disorder is a secondary effect of systemic malignancies such as squamous cell carcinomas, before they invade, compress or meta sta sise to the nervous system. It predominantly affects the grey matter and limbic system and may be an immunemediated disease. Para neo plastic disorder includes paraneoplastic limbic encephalitis, focal and brainstem encephalitis, motor neuron dysfunction (upper and lower motor signs), subacute sensory or peripheral neuropathy, cerebellar degeneration, retinopathy, autonomic dysfunction and myasthenic syndrome (Scaravilli 1999) . Symptoms have a subacute progression which precedes diagnosis of malignancy. Paraneoplastic limbic encephalitis leads to personality changes, irritability, memory loss (anterograde or retrograde), seizures, altered consciousness and focal deficits. Brainstem involvement causes diplopia, gaze abnormalities, facial numbness, dysarthria and dysphagia. Cerebellar symptoms include problems with balance, gait and ataxia. Underlying primary malignancy such as lung, testicular or breast carcinomas need to be excluded. Routine blood tests may be abnormal. Testing for tumour markers such as antineuronal and antiAChR antibodies, voltagegated potassium and calcium channel antibodies, carcinoembryonic antigen, cancer antigen 125 and prostatespecific antigen should be considered. Computed tomography of the chest, abdomen and pelvis can aid diagnosis of malignancy. Brain MRI may show temporal lobe abnormalities but is nonspecific. Inflammatory cells and negative cytology are apparent on lumbar puncture. Treatment of the underlying cancer will not necessarily lead to improvement of symptoms. Specific immunosuppressive therapies have been tried (KeimeGuibert 2000).
Inflammatory/autoimmune causes
Inflammatory and autoimmune disorders affecting the CNS have various aetiologies. Some of the rare hereditable causes of cognitive impairment and dementia are listed in Box 3.
Multiple sclerosis
Over half of people with multiple sclerosis (MS) develop some cognitive impairment, especially in the progressive forms. The exact cause of MS is probably multifactorial, involving genetic pre disposition and autoimmune and environmental factors. Multiple sclerosis is a multifocal demyelinating disorder usually characterised by periods of relapse and remission, although it can have a progressive pattern. It is more common in women than in men. Depression is common, with raised suicide risk. Psychosis is uncommon in MS and is distinct from schizophrenia as it has a later age at onset, quicker resolution, fewer relapses, better response to treatment and a better prognosis (Jefferies 2006) . Schizophreniform psychosis may be secondary to steroid treatment. Cognitive deficits may precede other symptoms, progress slowly and can be severe. The main cognitive decline occurs in attention, concentration, verbal fluency, comprehension, naming, executive func tion ing and memory. Magnetic resonance imaging reveals brain atrophy and ventricle enlargement. Oligoclonal bands are seen in the CSF.
Treatment of underlying depression is with selective serotonin reuptake inhibitors and/ or cognitive-behavioural therapy. Donepezil therapy for memory and cognitive dysfunction has undergone trials with some positive results (Krupp 2004) .
Neurosarcoidosis
This multisystemic granulomatous disease principally affects the lungs. It can also involve the CNS, causing cranial nerve palsies (e.g. facial palsy), delirium, seizures and peripheral neuropathy. It can occur at any age, but is most common in young adults. Women and people from certain ethnic groups are most likely to be affected (e.g. African Americans). In the rare instances that children have sarcoidosis, those less than 4 years of age may present with a distinct form, causing enlarged lymph nodes in the chest, skin lesions and eye swelling or redness. Around 10% of patients have cognitive, psychotic and neuropsychiatric complications (Wirnsberger 1998) . There is raised serum angiotensinconverting enzyme (ACE), and CSF examination shows raised ACE, proteins, cell count and oligoclonal bands. Multiple white matter lesions are evident on MRI. A history of sarcoidosis, chest Xray and nerve biopsy can confirm diagnosis.
Systemic and CNS vasculitis
Vasculitis is a systemic disorder of heterogeneous origin. It commonly involves the vertebral and basilar arteries (posterior circulation) and may lead to cerebellar and cerebral infarction. The cause can be primary, for example giant cell arteritis or Takayasu's arteritis (inflammation of the aorta); secondary, for example rheumatoid disease or infections (hepatitis B, HIV); or iatrogenic, from drugs such as sulfonamides.
Vasculitis may present with fever, night sweats and MSlike symptoms with a relapsingremitting course. Severe headaches are common. Optic neuropathy, mood problems, personality changes and multifocal/focal neurological deficits or rapidly progressive dementia may occur. Serological markers such as antineutrophil cyto plasmic antibodies (ANCA) and erythrocyte sedimentation rate may be raised. The CSF may show inflammatory cells and oligoclonal immuno globulin G (IgG) bands. Contrast angiography and MRI can be helpful but is nonspecific (Kuker 2007) .
Immunotherapy achieves a partial response of cognitive and psychiatric features.
Coeliac disease (nontropical sprue)
About 10% of people with coeliac disease experi ence CNS complications, but there are few recorded cases of dementia, mostly case series (e.g. Collin 1991; William 2006) . Coeliac disease is an auto immune disease with genetic preponderance. There may be a higher prevalence of gluten sensitivity in some genetic neurodegenerative disorders. Chronic immunemediated inflammation, lympho cytic infiltration or vasculitis of the CNS lead to irreversible neuronal, glial or axonal damage. Gastrointestinal symptoms include weight loss, 
Behçet disease
The aetiology of Behçet disease is unknown. It is a chronic, relapsing, multisystemic inflammatory disorder. Neurological complications include encephalopathy, sterile meningoencephalitis, cranial neuropathies, and cortical motor and sensory deficits. Chronic, progressive involvement of the CNS occurs in 10-20% of patients with Behçet disease, particularly males in whom the disease began at an early age. In the terminal stage of the disease, 3-6% of patients develop dementia (Kaklamani 1998) . When present, dementia is insidious with slow progression (Lishman 1998 The acute phase of neurological involvement responds well to highdose systemic corticosteroids, which can be supplemented with cytotoxic agents (cyclophosphamide, chlorambucil and metho trexate). In contrast, chronic progressive CNS disease responds poorly to treatment. In one study, 20% of patients with chronic neurological involve ment died within 7 years (AkmanDemir, 1996) .
Systemic lupus erythematosus
Systemic lupus erythematosus is a multisystemic autoimmune disorder that has direct effects on the CNS. These can be caused by autoantibodies (antiphospholipid, anti ribosomalP protein auto antibodies), cytokines and longterm sideeffects of gluco cortico steroids. The disease is more common in women. Clinical features include fever, malaise, maculopapular rash, photosensitivity, oral ulcers and nonerosive arthritis. (Kirk 1991) .
If suspected, encephalopathy should be excluded. Investigations may reveal anaemia, leukopoenia, thrombocytopoenia, elevated ESR, antibodies against doublestranded DNA (anti dsDNA antibodies) and antineuronal antibodies (ANA). Antineuronal antibodies and oligoclonal bands are present in more than half of patients. Viral serology is negative. Proteinuria and renal casts, and raised CSF protein and cell count may be found. Nonspecific cerebral atrophy, focal hyper intensities and widespread vasculopathy may be detected on MRI. Skin biopsy can aid diagnosis.
Treatment includes corticosteroids with or with out immunosuppressive drugs. Lupusinducing psychotropic drugs such as chlorpromazine, carbamazepine and lithium should be avoided.
Sjögren syndrome
This is an autoimmune disorder which targets moistureproducing glands, causing mouth and eye dryness. It is often associated with other auto immune disorders, such as rheumatoid arthritis, systemic lupus erythematosus and scleroderma. It occurs more commonly in women. Cognitive impairment can occur but is rare and subtle.
Investigations include the Schirmer test, eye stain dye tests and slit lamp examination. Blood testing for rheumatoid factors and antinuclear antibodies is helpful.
General treatments include artificial tears, eye ointment (methylcellulose), steroids and immuno suppressive drugs (Ampelas 2001).
Conclusions
It is important that patients presenting with dementia, particularly at a younger age than usual, receive an appropriate work up. Often, they are referred to psychiatric teams because of mood, psychotic or behavioural disturbances. Unless diagnosed early, these individuals are at risk of losing out on treatment that could alleviate, control or even reverse some of the symptoms. Earlyonset dementia also has medicolegal implications for treating clinicians, who would be expected to make adequate efforts to identify the under lying aetiology.
Clues to the underlying cause of a rare dementia may be sparse, although a family history may point to an inherited condition (Box 3). A comprehensive clinical examination with appropriate investi ga tions will help diagnosis, and seeking a specialist opinion from a physician or neurologist is highly recommended for atypical presentations.
Although psychiatrists might have theoretical knowledge of rare dementias, they are unlikely to encounter many cases in daytoday practice. We hope that the overview of causes and estimated prevalence rates (Table 1 ) presented in our two articles will guide clinicians in prioritising investigations, planning treatment and making referrals to appropriate medical colleagues. 
